The basic biochemistry and molecular events of hormone therapy

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Prostate cancer (PCa) response to hormone therapy is complex, involving intricate autocrine and paracrine signaling.
• Androgen suppression is a cornerstone of PCa treatment, but resistance mechanisms emerge.
• Understanding the molecular underpinnings of PCa's response to therapy is crucial for improving outcomes.

Purpose of the Study:

• To elucidate the molecular signaling networks involved in prostate cancer's response to androgen suppression.
• To identify key cellular pathways and mechanisms mediating tumor apoptosis and cytotoxicity during hormonal therapy.
• To highlight the need for novel therapeutic strategies targeting the androgen receptor (AR) signaling axis.

Main Methods:

• Review and synthesis of emerging data on molecular responses in prostate cancer.
• Analysis of signaling pathways including transforming growth factor-beta (TGF-β), insulin-like growth factor-1 (IGF-1), and vascular endothelial growth factor (VEGF).
• Evaluation of mechanisms of direct antitumor cytotoxicity by hormonal agents and antiandrogen development.

Main Results:

• Identified complex autocrine/paracrine signaling networks mediating tumor response to androgen suppression.
• Highlighted the role of TGF-β, IGF-1, and VEGF signaling axes in apoptotic response to therapy.
• Revealed persistent androgen receptor signaling activation and residual androgens in advanced prostate tumors despite castration.

Conclusions:

• Optimal efficacy of hormonal therapy for prostate cancer requires a multitargeted approach.
• Targeting all contributions to the androgen receptor signaling axis within the tumor microenvironment is essential.
• Development of antiandrogens with irreversible androgen receptor inhibition is important.